Skip to content

History and Nosology

TL;DR — Fibromyalgia descends from "fibrositis," a term Gowers coined in 1904 for presumed fibrous-tissue inflammation that biopsy never confirmed (Gowers 1904, PMID 20761312; Galvez-Sánchez 2020, PMID 32340369). Smythe and Moldofsky rebuilt the entity in 1977 around tender points and non-restorative sleep (Smythe & Moldofsky 1977, PMID 199304), Yunus added the first controlled data in 1981 (PMID 6944796), and the ACR's 1990 criteria institutionalized it (Wolfe 1990, PMID 2306288). Since then two debates have defined the field: (1) legitimacy — whether FM is underrecognized neurology or the medicalization of distress (Ehrlich 2003, PMID 12913918; Wolfe & Walitt 2013, PMID 23820862), and (2) structure — whether FM is a discrete entity or the extreme of a continuous "polysymptomatic distress"/fibromyalgianess dimension, a view Wolfe himself came to hold against his own 1990 criteria (Wolfe 1997, PMID 9166001; Wolfe 2013, PMID 23424058). The nociplastic-pain descriptor (2016) and ICD-11's chronic primary pain gave FM a mechanistic-sounding home (Kosek 2016, PMID 26835783; Treede 2019, PMID 30586067), but the category was contested at birth (Granan 2017, PMID 27984528). Nothing short of a validated mechanism, marker, or latent-structure result is likely to settle the question.

Timeline: fibrositis → fibromyalgia → nociplastic pain

Year Event Source (PMID)
1642–1800s "Muscular rheumatism" descriptions (de Baillou and successors) 32340369
1904 Gowers coins fibrositis in a lecture on lumbago, positing fibrous-tissue inflammation; Stockman claims supporting pathology (never replicated) 20761312; 32340369
1947 Boland proposes "psychogenic rheumatism" — the psychological reading of the same clinical material 32340369
1968 Traut describes "non-articular rheumatism": generalized pain, tiredness, sleep disorder, palpation-tender regions 32340369
1975 Moldofsky: alpha-rhythm intrusion into NREM sleep in "fibrositis"; stage-4 sleep deprivation reproduces musculoskeletal symptoms in healthy subjects — "non-restorative sleep syndrome" hypothesis 169541
1976 Hench coins the term fibromyalgia (fibro- + myo- + -algia) 32340369; 15361321
1977 Smythe & Moldofsky propose first criteria: widespread pain, unrefreshing sleep, tenderness at 12 of 14 sites 199304; 32340369
1981 Yunus et al: first controlled clinical study (50 patients vs 50 matched controls) and first data-based criteria; symptoms (fatigue, poor sleep, IBS, headache) move to the center 6944796
1987 American Medical Association accepts FM as a disease; ACR forms criteria committee 32340369
1990 ACR classification criteria: widespread pain + ≥11/18 tender points; "fibromyalgia" replaces "fibrositis"; primary/secondary distinction abandoned 2306288
1992 WHO recognition; ICD-10 code M79.7 32340369
2010–2016 ACR preliminary diagnostic criteria (WPI + symptom severity), self-report modification, 2016 revision with generalized-pain criterion — tender points abandoned 20461783; 21285161; 27916278
2016 IASP task force proposes third mechanistic descriptor → nociplastic pain 26835783
2019 AAPT dimensional diagnostic framework; ICD-11 places FM under chronic primary pain 30453109; 30586067; 30586068
2021 IASP clinical criteria and grading system for musculoskeletal nociplastic pain 33974577

Two details of this arc matter for interpretation. First, the founding pathology claim (fibrous-tissue inflammation) was refuted by biopsy, so the name "fibrositis" survived for decades without its mechanism (Galvez-Sánchez 2020, PMID 32340369). Second, the content of the diagnosis has changed repeatedly — tender points were not part of the pre-1977 concept, were mandatory 1990–2010, and are absent from every criteria set since — so patients diagnosed under different eras are not the same population (Wolfe & Walitt 2013, PMID 23820862; Jones 2015, PMID 25323744).

The contested-illness history

FM has been fought over more openly than almost any other rheumatologic diagnosis; Wolfe's own retrospective is titled "Fibromyalgia wars" (Wolfe 2009, PMID 19342721). Even sympathetic reviews concede that definition, pathogenesis, diagnosis, and treatment "remain points of contention, with some even contesting its existence" (Häuser & Fitzcharles 2018, PMID 29946212).

The skeptical position holds that the diagnosis reifies distress. Its sharpest published statement is Ehrlich's editorial "Pain is real; fibromyalgia isn't" (Ehrlich 2003, PMID 12913918). Wolfe & Walitt argue that FM is "closely allied with and often indistinguishable from" neurasthenia — a 19th-century diagnosis abandoned once it was perceived as psychological — and that FM's status as a "real disease" is buttressed by social forces: official criteria, patient and professional organizations, pharmaceutical companies, disability access, and the legal and academic communities (Wolfe & Walitt 2013, PMID 23820862). Empirical ammunition for this side includes: tender points tracking distress rather than a discrete pathology (Croft 1994, PMID 7950521; Wolfe 1997, PMID 9166001); community physician diagnosis being weakly related to any criteria definition (κ ≈ 0.30; Srinivasan 2019, PMID 31777779); and diagnostic-era observations that criteria changes re-engineer the patient population (Wolfe & Walitt 2013, PMID 23820862).

The legitimacy position holds that FM is a real, underdiagnosed disorder of pain processing. Its empirical base: symptom clusters replicate across cultures with criteria-based prevalence ~2–4% worldwide (Häuser 2015, PMID 27189527; Queiroz 2013, PMID 23801009); most criteria-positive people in the community have never received the diagnosis (73% undiagnosed in the US NHIS, Walitt 2015, PMID 26379048; survey prevalence 6.4% vs 1.1% diagnosed in Olmsted County, Vincent 2013, PMID 23203795); diagnosis reduces downstream healthcare costs rather than inflating them (Annemans 2008, PMID 18311794); and the condition carries measurable excess suicide mortality (Dreyer 2010, PMID 20583101; Wolfe 2011, PMID 20662040). Patients experience the contested status directly, as "invalidation" — disbelief, stigmatization, suspicion of exaggeration (Galvez-Sánchez 2020, PMID 32340369) — treated further in patient experience and advocacy.

Both positions are compatible with the same data to an uncomfortable degree, which is why the argument has lasted 40 years. The wiki's stance: report the measurements, flag the frame.

Discrete entity or end of a continuum?

This is the central nosological question, and its historiography is unusual because the strongest anti-entity evidence comes from the architect of the entity's criteria.

  • Croft (population data, 1994–1996): in a general-population sample, tender point counts rose continuously with pain extent, depression, fatigue, and poor sleep; most people with chronic widespread pain had <11 tender points (27/45; 60%); conclusion — tender points are "a measure of general distress" and "fibromyalgia does not seem to be a distinct disease entity" (Croft 1994, PMID 7950521). The follow-up asked directly, "is fibromyalgia just one end of a continuous spectrum?" and answered yes: tender points and pain associate across the whole population, not just in the clinical subgroup (Croft 1996, PMID 8774169).
  • Wolfe (clinic data, 1997): in 627 clinic patients, distress rose linearly with tender point count with no discontinuity at any threshold; the tender point count functions as "a 'sedimentation rate' for distress," and "there seems to be no rationale for treating fibromyalgia as a discrete disorder" (Wolfe 1997, PMID 9166001).
  • "Fibromyalgianess" (2009): Wolfe names the underlying dimension — a symptom-reporting trait measurable in any rheumatic disease, not just FM (Wolfe 2009, PMID 19479689). The operationalization is the polysymptomatic distress (PSD) scale (widespread pain index + symptom severity, range 0–31), with severity bands from none (0–3) to very severe (20–31) (Galvez-Sánchez 2020, PMID 32340369).
  • Population dimensionality (2013): in 2,445 German adults, relations between PSD and all predictors (anxiety, depression, somatic symptoms, quality of life) were smooth and non-disordered — "additional evidence against the hypothesis that fibromyalgia is a discrete disorder and in support of a dimensional or spectrum disorder"; 38.5% of criteria-positive persons also met DSM-5 physical-symptom-disorder criteria (Wolfe 2013, PMID 23424058).

The trajectory is notable: Wolfe led the 1990 criteria committee (Wolfe 1990, PMID 2306288), then spent two decades publishing evidence that the category his criteria created is a segment of a continuum (Wolfe 1997, PMID 9166001; Wolfe 2009, PMID 19342721; Wolfe 2013, PMID 23424058). The practical residue of this evolution is that modern criteria keep a categorical threshold for clinical use while explicitly measuring severity on the continuous PSD scale (Wolfe 2016, PMID 27916278; Galvez-Sánchez 2020, PMID 32340369).

The lumping alternative. Yunus accepts continuity but redraws the boundary outward: FM, IBS, tension headache, chronic fatigue syndrome and related disorders are one family — "central sensitivity syndromes" — unified by central sensitization, though he concedes the sensitization evidence is weak or absent for several members (Yunus 2007, PMID 17350675). The AAPT framework similarly treats FM as a dimensional syndrome with core criteria, common features, comorbidities, consequences, and putative mechanisms rather than a point diagnosis (Arnold 2019, PMID 30453109). See comorbidities and overlap for the overlapping-conditions data.

Nociplastic pain: the concept and its critics

The 2016 IASP task force asked whether chronic pain states with neither ongoing nociception nor a demonstrable somatosensory lesion need their own mechanistic descriptor, and proposed one (Kosek 2016, PMID 26835783). As adopted, nociplastic pain denotes pain from altered nociception — augmented central pain and sensory processing with altered pain modulation — in the absence of sufficient tissue or nerve damage, with FM the canonical example; the clinical signature includes multifocal pain disproportionate to peripheral findings, co-occurring fatigue, sleep, memory and mood symptoms, and poor response to peripherally directed treatment (Fitzcharles 2021, PMID 34062144). The 2021 IASP criteria formalize clinical ascertainment and grade cases "possible" or "probable" (Kosek 2021, PMID 33974577). ICD-11's chronic primary pain gives the family a coding home in which pain is a disease in its own right rather than a symptom (Treede 2019, PMID 30586067; Nicholas 2019, PMID 30586068).

Criticisms, published from the start:

  • Prematurity. The direct reply to the 2016 proposal argued a third descriptor was not yet justified — the title says it: "We do not need a third mechanistic descriptor for chronic pain states! Not yet." (Granan 2017, PMID 27984528).
  • Descriptor ≠ mechanism. The proposal itself is framed as a question about clinical labeling (Kosek 2016, PMID 26835783); the underlying mechanisms are acknowledged as "not entirely understood" even in advocacy reviews (Fitzcharles 2021, PMID 34062144). Whether "augmented CNS processing" is cause, consequence, or correlate of the clinical state is exactly the unresolved question of central pathophysiology.
  • Boundary instability. Nociplastic pain can coexist with nociceptive/neuropathic pain in "mixed pain" states (Fitzcharles 2021, PMID 34062144), which makes the category hard to falsify in individual patients; and peripheral findings in FM (small-fiber pathology — see peripheral pathophysiology) blur the "absence of tissue/nerve damage" clause (Galvez-Sánchez 2020, PMID 32340369, notes small- and large-fiber neuropathy evidence).

What would settle the nosology question

Candidate arbiters, each with its current status:

Arbiter What it would show Status
Validated diagnostic biomarker A discrete biological boundary (or its absence) None validated (Galvez-Sánchez 2020, PMID 32340369) — see biomarkers
Latent-structure analyses at population scale Taxon vs dimension Existing analyses support dimension (Wolfe 2013, PMID 23424058; Croft 1996, PMID 8774169); no definitive taxometric study located in this review
Mechanistic stratification predicting treatment response Clinically consequential subtypes Nociplastic grading published but unvalidated against outcomes (Kosek 2021, PMID 33974577); AAPT criteria not yet validated (Galvez-Sánchez 2020, PMID 32340369)
Longitudinal case stability Whether "case" is a state or trait ~25–30% of previously diagnosed patients no longer met 1990 criteria at re-examination (Wolfe 2010, PMID 20461783; Galvez-Sánchez 2020, PMID 32340369)
Etiologic discovery (genetics, autoimmunity) An external anchor for the category Open — see genetics and risk factors and autoimmunity and inflammation

Open questions

  • Has any adequately powered taxometric or latent-class analysis tested discrete-vs-dimensional structure using post-2016 criteria items? The dimensional conclusion rests on regression smoothness (Wolfe 2013, PMID 23424058) and population tender-point gradients (Croft 1996, PMID 8774169), not on formal latent-structure methods.
  • If FM diagnosis is applied to a continuum, where should the threshold sit to maximize clinical utility (treatment response, prognosis) rather than classification agreement? Current thresholds descend from fit to 1990-era clinic samples (Wolfe 2010, PMID 20461783; Wolfe 2016, PMID 27916278).
  • Does the nociplastic grading system (Kosek 2021, PMID 33974577) identify patients with distinct treatment response or biology, or does it re-label the FM/PSD continuum?
  • Was the sleep-based causal model (alpha-delta intrusion → symptoms; Moldofsky 1975, PMID 169541) ever adequately tested as a mechanism rather than a correlate? See sleep, fatigue, cognition.
  • Can the neurasthenia analogy (Wolfe & Walitt 2013, PMID 23820862) be made empirically tractable — e.g., by comparing symptom-structure and outcome data across historical diagnostic cohorts — or is it permanently rhetorical?

References

  1. Gowers WR. A Lecture on Lumbago: Its Lessons and Analogues. Br Med J. 1904;1(2246):117-21. PMID 20761312
  2. Galvez-Sánchez CM, Reyes del Paso GA. Diagnostic Criteria for Fibromyalgia: Critical Review and Future Perspectives. J Clin Med. 2020;9(4):1219. PMID 32340369
  3. Inanici F, Yunus MB. History of fibromyalgia: past to present. Curr Pain Headache Rep. 2004;8(5):369-78. PMID 15361321
  4. Moldofsky H, et al. Musculoskeletal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects. Psychosom Med. 1975;37(4):341-51. PMID 169541
  5. Smythe HA, Moldofsky H. Two contributions to understanding of the "fibrositis" syndrome. Bull Rheum Dis. 1977;28(1):928-31. PMID 199304
  6. Yunus M, et al. Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum. 1981;11(1):151-71. PMID 6944796
  7. Wolfe F, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33(2):160-72. PMID 2306288
  8. Wolfe F, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010;62(5):600-10. PMID 20461783
  9. Wolfe F, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol. 2011;38(6):1113-22. PMID 21285161
  10. Wolfe F, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46(3):319-329. PMID 27916278
  11. Kosek E, et al. Do we need a third mechanistic descriptor for chronic pain states? Pain. 2016;157(7):1382-1386. PMID 26835783
  12. Arnold LM, et al. AAPT Diagnostic Criteria for Fibromyalgia. J Pain. 2019;20(6):611-628. PMID 30453109
  13. Treede RD, et al. Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for ICD-11. Pain. 2019;160(1):19-27. PMID 30586067
  14. Nicholas M, et al. The IASP classification of chronic pain for ICD-11: chronic primary pain. Pain. 2019;160(1):28-37. PMID 30586068
  15. Kosek E, et al. Chronic nociplastic pain affecting the musculoskeletal system: clinical criteria and grading system. Pain. 2021;162(11):2629-2634. PMID 33974577
  16. Wolfe F. Fibromyalgia wars. J Rheumatol. 2009;36(4):671-8. PMID 19342721
  17. Ehrlich GE. Pain is real; fibromyalgia isn't. J Rheumatol. 2003;30(8):1666-7. PMID 12913918
  18. Wolfe F, Walitt B. Culture, science and the changing nature of fibromyalgia. Nat Rev Rheumatol. 2013;9(12):751-5. PMID 23820862
  19. Croft P, et al. Population study of tender point counts and pain as evidence of fibromyalgia. BMJ. 1994;309(6956):696-9. PMID 7950521
  20. Croft P, et al. More pain, more tender points: is fibromyalgia just one end of a continuous spectrum? Ann Rheum Dis. 1996;55(7):482-5. PMID 8774169
  21. Wolfe F. The relation between tender points and fibromyalgia symptom variables: evidence that fibromyalgia is not a discrete disorder in the clinic. Ann Rheum Dis. 1997;56(4):268-71. PMID 9166001
  22. Wolfe F. Fibromyalgianess. Arthritis Rheum. 2009;61(6):715-6. PMID 19479689
  23. Wolfe F, et al. Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care Res (Hoboken). 2013;65(5):777-85. PMID 23424058
  24. Yunus MB. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum. 2007;36(6):339-56. PMID 17350675
  25. Fitzcharles MA, et al. Nociplastic pain: towards an understanding of prevalent pain conditions. Lancet. 2021;397(10289):2098-2110. PMID 34062144
  26. Granan LP. We do not need a third mechanistic descriptor for chronic pain states! Not yet. Pain. 2017;158(1):179. PMID 27984528
  27. Häuser W, et al. Fibromyalgia. Nat Rev Dis Primers. 2015;1:15022. PMID 27189527
  28. Queiroz LP. Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep. 2013;17(8):356. PMID 23801009
  29. Walitt B, et al. The Prevalence and Characteristics of Fibromyalgia in the 2012 National Health Interview Survey. PLoS One. 2015;10(9):e0138024. PMID 26379048
  30. Vincent A, et al. Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care Res (Hoboken). 2013;65(5):786-92. PMID 23203795
  31. Annemans L, et al. Health economic consequences related to the diagnosis of fibromyalgia syndrome. Arthritis Rheum. 2008;58(3):895-902. PMID 18311794
  32. Dreyer L, et al. Mortality in a cohort of Danish patients with fibromyalgia: increased frequency of suicide. Arthritis Rheum. 2010;62(10):3101-8. PMID 20583101
  33. Wolfe F, et al. Mortality in fibromyalgia: a study of 8,186 patients over thirty-five years. Arthritis Care Res (Hoboken). 2011;63(1):94-101. PMID 20662040
  34. Srinivasan S, et al. The Problematic Nature of Fibromyalgia Diagnosis in the Community. ACR Open Rheumatol. 2019;1(1):43-51. PMID 31777779
  35. Jones GT, et al. The prevalence of fibromyalgia in the general population: a comparison of the ACR 1990, 2010, and modified 2010 classification criteria. Arthritis Rheumatol. 2015;67(2):568-75. PMID 25323744
  36. Häuser W, Fitzcharles MA. Facts and myths pertaining to fibromyalgia. Dialogues Clin Neurosci. 2018;20(1):53-62. PMID 29946212